185200-33-3

Usage

Uses

Used in Pharmaceutical Industry:
Benzeneacetic acid, 3-bromo-4-nitro-, methyl ester is utilized as an active pharmaceutical ingredient for its strong antibacterial and antifungal capabilities. It is particularly valuable in the development of medications targeting a wide range of infections, enhancing the effectiveness of treatments and contributing to the management of antibiotic resistance.
Used in Agricultural Chemicals:
In the agricultural sector, Benzeneacetic acid, 3-bromo-4-nitro-, methyl ester serves as a key component in the formulation of fungicides and bactericides. Its inclusion in these products helps protect crops from various diseases, thereby ensuring higher yields and better crop quality.
Used in Dye and Perfume Manufacturing:
Benzeneacetic acid, 3-bromo-4-nitro-, methyl ester is employed as a raw material in the production of dyes and perfumes. Its unique chemical properties allow for the creation of vibrant colors and distinct fragrances, enriching the palette of options available in these industries.
Used in Organic Compound Synthesis:
This ester is also a crucial intermediate in the synthesis of various organic compounds. Its reactivity and functional groups make it a valuable building block for the creation of complex molecules with specific applications in research and industry.

Upstream product

• 67-56-1 methanol 
• 90004-95-8 3-Brom-4-nitro-phenylessigsaeure 
• 150529-73-0 methyl 2-(3-bromophenyl)acetatee 
• 1878-67-7 3-Bromophenylacetic acid 
• 53088-68-9 methyl 3-chlorophenylacetate 
• 594844-44-7 2-(3-bromo-4-nitrophenyl)malonic acid tert-butyl ester methyl ester 
• 31938-07-5 (3-bromophenyl)acetonitrile 
• 124840-60-4 3-Brom-4-nitro-benzylcyanid 

Downstream Products

• 209809-20-1 4-amino-3-bromophenylacetic acid methyl ester 
• 924309-89-7 methyl (4-nitro-3-trimethylsilylethynylphenyl)acetate 
• 594844-45-8 (3-dimethylamino-4-nitrophenyl)acetic acid methyl ester 
• 317356-81-3 methyl 3-bromo-4-[N'-(2-bromophenyl)ureido] phenylacetate 
• 317356-78-8 methyl 3-bromo-4-[N'-(2-chlorophenyl)ureido] phenylacetate 
• 317356-75-5 methyl 3-bromo-4-[N'-(2-methylphenyl)ureido] phenylacetate 
• 317356-82-4 (3-bromo-4-[N'-(2-bromophenyl)ureido]phenyl)acetic acid 
• 317356-79-9 (3-bromo-4-[N'-(2-chlorophenyl)ureido]phenyl)acetic acid 
• 317356-76-6 (3-bromo-4-[N'-(2-methylphenyl)ureido]phenyl)acetic acid 
• 924309-81-9 (3-ethyl-4-[N'-(2-methylphenyl)ureido]phenyl)acetic acid 
• 924309-77-3 methyl (4-amino-3-ethylphenyl)acetate 
• 924309-90-0 methyl (3-ethynyl-4-nitrophenyl)acetate 
• 317356-83-5 C₂₈H₂₆Br₂FN₃O₅ 
• 317356-80-2 C₂₈H₂₆BrClFN₃O₅ 

Relevant academic research and scientific papers

Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists

A series of benzoic acid derivatives was synthesized as VLA-4 antagonists. Introduction of chlorine or bromine into the 3-position on the central benzene of the diphenylurea portion as in lead compound 2 led to improvement in the pharmacokinetic properties. In particular, 12l demonstrated an acceptable plasma clearance and bioavailability in mice and rats as well as dogs (mice, CL = 18.5 ml/min/kg, F = 28 %; rats, CL = 5.2 ml/min/kg, F = 36 %; dogs, CL = 3.6 ml/min/kg, F = 55 %). Additionally, 12l exhibited potent activity with an IC50 value of 0.51 nM and efficacy by oral administration at a dosage of 10 mg/kg in a rat pleurisy model.

ESTER DERIVATIVE AND MEDICINAL USE THEREOF

A therapeutic agent for hyperlipidemia which has no side effects on the liver unlike conventional MTP inhibitors and has excellent MTP inhibitory activity. Also, provided is an ester compound represented by the general formula (1): or a pharmaceutically a

ESTER COMPOUND AND MEDICINAL USE THEREOF

A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1") (wherein ???R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.; ???X is -COO- or -CON(R10)-; ???R3 and R4 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; ???R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; ???R8 and R9 are each independently hydrogen atom, C1-C6 alkyl, -CON(R18)(R19) or -COO(R20), etc.; ???ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; ???Alk1 and Alk2 are each independently alkanediyl, etc.; ???l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.

VLA-4 inhibitor compounds

Compounds that selectively inhibit the binding of ligands to alpha4beta1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.